Bisphosphonates and atherosclerosis: Why?

Lupus

Volumn 14, Issue 9, 2005, Pages 773-779

  Bevilacqua, Maurizio ^a   Dominguez, L J ^b   Rosini, S ^c   Barbagallo, M ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Abiogen Pharma ^*  (Italy)

Author keywords

Atherosclerosis; Bisphosphonates; Osteoporosis; Vascular calcifications

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; MEVINOLIN; NERIDRONIC ACID; PAMIDRONIC ACID; PYROPHOSPHORIC ACID DERIVATIVE; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; BONE METASTASIS; CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DEGRADATION; DISEASE MODEL; DRUG ACCUMULATION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG USE; FOAM CELL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VALVE; HUMAN; HYPERCALCEMIA; LIPID STORAGE; MACROPHAGE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; REVIEW; SYSTOLIC HYPERTENSION;

APOPTOSIS; ATHEROSCLEROSIS; BONE RESORPTION; CALCINOSIS; CHOLESTEROL; DIPHOSPHONATES; HUMANS; MACROPHAGES; MEVALONIC ACID; MOLECULAR STRUCTURE;

EID: 26244467270     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2219oa     Document Type: Review

References (31)

1. Rogers MJ, Gordon S, Benford HL et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961-2978.
2. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action, Mini Rev Med Chem 2004; 4: 711-719.
3. Rosenblum IY, Flora L, Eisenstein R. The effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on a rabbit model of atheroarteriosclerosis. Atherosclerosis 1975; 22: 411-424.
4. Kramsch DM, Chan CT. The effect of agent interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits. Circ Res 1978; 42: 562-571.
5. Kramsch DM, Aspen AJ, Rozler LJ. Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science 1981; 213: 1511-1512.
6. Ylitalo R, Oksala O, Yla-Herttuala S, Ylitalo P. Effects of clodronate (dichloro-methylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med 1994; 123: 769-776.
7. Zhu B-Q, Sun Y-P, Sievers RE, Isenberg WM, Moorhead TJ, Parmley WW. Effects of etidronate and lovastatin on the regression of atherosclerosis in cholesterol-fed rabbits. Cardiology 1994; 85: 370-377.
8. Koshiyma H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab 2000; 85: 2793-2796.
9. Acierno LJ. Atherosclerosis (arteriosclerosis). In Acieno LJ ed. The History of Cardiology (Edited by Acierno LJ), New York: Parthenon Publishing Group Inc. 1994: 109-126.
10. Demer LL, Tintut Y. Mineral exploration: search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture. Arterioscler Thromb Vasc Biol 2003; 23: 1739-1743.
11. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R. Vascular ossification - calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovascular Diabetology 2005; 4: 4.
12. Fleisch H, Rusell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165: 1262-1264.
13. Fleisch H. Bisphosphonates: mechanisms of action. Endocr rev 1998; 19: 80-100.
14. Ylitalo R, Monkkonen J, Urtti A, Ylitalo P. Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med 1996; 127: 200-206.
15. Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Comm 2005; 328: 746-750.
16. Ikehira H, Furuichi Y, Kinjo M, Yamamoto Y, Aoki T. Multiple extrabone accumulations of technetium-99 m-HMDP. J Nucl Med Technol 1999; 27: 41-42.
17. Ylitalo R, Kalliovalkama J, Wu X et al. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol 1998; 83: 125-131.
18. Rogers MJ, Xiong X, Ji X et al. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake. Pharm Res 1997; 14: 625-630.
19. Ross R. Atherosclerosis-an inflammatory disease. New Engl J Med 1999; 340: 115-126.
20. Monkkonen J, Taskinen M, Auriola SO, Urtti A. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound and free bisphosphonates in vitro. J Drug Targeting 1994; 2: 299-308.
21. Ylitalo R, Syvala H, Tuohimaa P, Ylitalo P. Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate. Pharmacol Toxicol 2002; 90: 139-143.
22. Ylitalo R, Monkkonen J, Yla-Herttuala S. Effects of liposome-encapsulated bisphosphonates on the acetylated LDL metabolism, lipid accumulation and viability of phagocyting cells. Life Sci 1998; 62: 413-422.
23. Tuominen OM, Hollmen M, Faakkola O, Monkkonen J, Ylitalo R. Suppression of viability and acetyl-LDL metabolism of RAW 264 macrophage-like and smooth muscle cells by bisphosphonates. Methods Find Exp Clin Pharmacol 2002; 24: 487-492.
24. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000; 373: 231-241.
25. Fleisch H, Rusell RGG, Bisaz S, Mühlbauer RC, Williams DA. The inhibitory effect of phosphonates of the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970; 1: 12-18.
26. Russell RGG, Smith R, Bishop MC, Price DA. Treatment of myositis ossificans progressive with a diphosphonate. Lancet 1972; 1: 10-11.
27. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817-824.
28. Cram RL, Barmada R, Geho WB, Ray RD. Diphosphonate treatment of calcinosis universalis. N Engl J Med 1971; 285: 1012-1013.
29. Meradji M, de Villeneuve VH, Huber J, de Bruijn WC, Pearse RG. Idiopathic infantile arterial calcification in siblings: radiologic diagnosis and successful treatment. J Pediatr 1978; 92: 401-405.
30. Shimshi M, Abe E, Fisher EA, Zaidi M, Fallon JT. Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice. Biochem Biophys Res Comm 2005; 328: 790-793.
31. Tanko LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporosis Int 2005; 16: 184-190.